<DOC>
	<DOC>NCT00823992</DOC>
	<brief_summary>This 2 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Patients will be randomized to receive taspoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) or placebo sc, in addition to their prescribed, pre-existing metformin therapy.After the first 24 weeks, patients on placebo will be switched to taspoglutide 20mg once weekly (after 4 weeks on taspoglutide 10mg once weekly) The anticipated time on study treatment is 12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes mellitus, receiving metformin at a stable dose of &gt;=1500mg/day for at least 12 weeks; HbA1c &gt;=6.5% and &lt;=9.5% at screening; BMI &gt;=30 and &lt;=50 kg/m2 at screening; stable weight +/5% for at least 12 weeks prior to screening. history of type 1 diabetes or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months; evidence of clinically significant diabetic complications; myocardial infarction, coronary artery bypass surgery, posttransplantation cardiomyopathy or stroke within the past 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>